Loading...
Please wait, while we are loading the content...
Similar Documents
Maury Hematopoietic Stem Cell Transplantation Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Regulatory T Cell Depletion Improves the + CD 25 + CD 4
| Content Provider | Semantic Scholar |
|---|---|
| Author | Maury, Sébastien Lemoine, François Michel Hicheri, Yosr Rosenzwajg, Michelle Badoual, Cécile Cheraï, Mustapha Beaumont, Jean-Louis Azar, Nabih Dhédin, Nathalie Sirvent, Anne Buzyn, Agnés Rubio, M. Vigouroux, Stéphane Montagne, Olivier Bories, Dominique Thoraval, Françoise Roudot‐ Vernant, Jean-Paul Cordonnier, Catherine Klatzmann, David Cohen, José L. |
| Copyright Year | 2010 |
| Abstract | a boon to patients with blood cancers. are needed, but this seemingly inappropriate encouragement of immune reactions in transplant recipients may prove effective way to free active T cells from inhibition so that they can fight cancer cells in the recipient. Further studies This preliminary study shows that depleting donor lymphocytes of inhibitory regulatory T cells can be a safe and successful immune control of the cancer cells by the infused Treg-depleted lymphocytes. experienced a graft-versus-host reaction after cell infusion were found to have survived longer, likely a result of the tumor cells as well. When the whole group was assessed 1 year after treatment, the patients who had reacted to the infused cells by developing graft-versus-host disease, a sign that the infused cells were likely attacking were eliminated with lymphopdepletive chemotherapy. These four patients, all of whom had Hodgkin s lymphoma, needed more infusions with the same Treg-depleted cells but now infused them immediately after recipient Tregs this low rate of response was a result of Treg cells present in the recipient, they treated four of the patients who two of the patients developed graft-versus-host disease for the first time in their transplant history. Hypothesizing that control of their malignancy. After receiving a new infusion of lymphocytes from which the Tregs had been removed, nor previously received an infusion of lymphocytes and had neither clinical manifestations of graft-versus-host disease cells that also provided graft-versus-tumor effects. They treated 17 patients with relapsed blood cancer who had authors of this study used the presence of graft-versus-host disease as a sign that there were active, functioning T the host s skin, liver, intestinal lining, and other internal organs a condition that is serious but can be treated. The graft-versus-host disease. Like the transplanted T cells that perceive cancer cells as foreign, T cells can also attack The beneficial graft-versus-tumor effect of transplantation can be accompanied by the not-so-desirable the infusion markedly improved the graft-versus-tumor effect and the patients survival. include regulatory T cells (Tregs), a class of T cells that dampens the immune response. Removing these cells before the malignancy, however. The reason for failure, Maury et al. have now shown, is that the donor cells can often when such patients suffer a relapse and donor T cells are infused into the patient. These infusions often fail to quell harnessed contain T cells that attack and destroy any remaining cancerous cells. This graft-versus-tumor effect is also blood cancers, and the donated cells not only engraft in bone to provide a source of healthy blood cells but also little immune activation is a good thing. Hematopoietic stem cells in the form of bone marrow are often used to treat Patients search for organ donors who are close genetic matches to avoid immune reactions. But sometimes a |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://www.assim.refer.org/portail/portail/nouveaux-liens_files/maury-et-al.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
